Literature DB >> 15993582

Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.

Rajni Garg1, Disha Patel.   

Abstract

As part of an ongoing effort in understanding the role of hydrophobicity in the design of nonpeptidic HIV protease inhibitors, the QSAR study on P2/P2' tetrahydropyrimidinone is presented in this report. Our results suggest that the balance of hydrophobicity and a volume- dependent polarizability term plays a key role in the inhibition of the viral protease by these inhibitors. The size of the substituent of ligands at particular positions that induce steric fit is crucial. The role of hydrophobicity in the design of tetrahydropyrimidinone is discussed. It has been found that a sufficient spread in the data is required to observe the optimum value of ClogP for these inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993582     DOI: 10.1016/j.bmcl.2005.05.087

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Microsphere preparation using the untoxic solvent glycofurol.

Authors:  Daniela Allhenn; Alf Lamprecht
Journal:  Pharm Res       Date:  2010-10-29       Impact factor: 4.200

2.  Hybrid-genetic algorithm based descriptor optimization and QSAR models for predicting the biological activity of Tipranavir analogs for HIV protease inhibition.

Authors:  A Srinivas Reddy; Sunil Kumar; Rajni Garg
Journal:  J Mol Graph Model       Date:  2010-03-24       Impact factor: 2.518

3.  Effect of ultra-high pressure homogenization on the interaction between bovine casein micelles and ritonavir.

Authors:  M Corzo-Martínez; M Mohan; J Dunlap; F Harte
Journal:  Pharm Res       Date:  2014-10-01       Impact factor: 4.200

4.  Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease.

Authors:  Rajni Garg; Barun Bhhatarai
Journal:  J Comput Aided Mol Des       Date:  2008-03-27       Impact factor: 3.686

5.  Developing a Flexible Pediatric Dosage Form for Antiretroviral Therapy: A Fast-Dissolving Tablet.

Authors:  Manjari Lal; Manshun Lai; Marcus Estrada; Changcheng Zhu
Journal:  J Pharm Sci       Date:  2017-05-10       Impact factor: 3.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.